| Objective: To investigate the feasibility and safety of the clinical application of hematological tumour immunotherapy by adoptive infusion of dentrtic cells and to provide case reference for clinical therapy by DC.Methods: Since 2000, we have cultured and amplified bone marrow mononuclear cells from the posterior superior iliac spine of two hematological tumour patients treated by standard chemotherapy(one is CR of AML-M2a, another is NR of MM) by two-step culture and differentiated some dendritic cells. These dendritic cells accredited were infused adoptively to the two patients.The clinical course was observed. Then we judged therapeutic effect, analyzed the two cases and reviewed the relative documents.Results :1.The first one, AML patients acquired the first CR after treated with one time of therapy of TA and two times of therapy of MA from March, 2003. Afterward we continused the intensive chemotherapy (TA, MA, 2 ID Arc , HA) .On 15th July, 2003, the chemotherapy was stopped for the patient and after 3 months intermission the first DC infusion was started. The DC infusion added up to 3 times before and after. It has no chemotherapy during the last twice intermission of DC infusion, the intermission between the second and the third to the last chemotherapy are respectively 4 months and 10 months. Through the course of treatment, the patient has not any adverse effects such as fever, chilly, shiver, skin rasru oppressed feeling in chest, short breatlu asthma etc, and has kept CR until relapse in February 2005. So far the chemotherapy intermission is 14... |
PDF Full Text Request